Ovarian Cancer

Sperm antigen 17 shows promise for ovarian cancer therapy

Published in Vaccine Weekly, July 3rd, 2002

by Maria G. Essig, MS, ELS, senior medical writer - A vaccine directed against sperm antigen 17 showed potential as a successful treatment for ovarian cancer, researchers in Texas report.

The expression of sperm antigen 17 (Sp17) in normal tissue is limited. Therefore, it holds potential as a vaccine target for diseased tissues that do express the antigen.

M. Chirivainternati and colleagues at the Don and Sybil Harrington Cancer Center in Amarillo, Texas, prepared cytotoxic T-lymphocytes (CTL) specific to Sp17 after determining the gene expression of Sp17. A ⁵¹Cr release assay confirmed the identity of the CTLs.

The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-07-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry